Cancer Treatment Today

Lynparza is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. ITs sue for maintenance of breast cancer is off-label. PARP inhibitors have been approved for the treatment of metastatic breast cancer in germline BRCA mutation (gBRCAm) carriers. The recent Olympia trial demonstrated improved progression-free and distant disease-free survival with adjuvant olaparib for gBRCAm carriers with HER2-negative high-risk early-stage breast cancer.
N.J. Tung et al, Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer, Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Tung, N., Garber, J.E. PARP inhibition in breast cancer: progress made and future hopes. Breast Cancer 8, 47 (2022).

NCCN Breast Cancer 2022